{"id":"W1983150990","doi":"10.1016/j.ygyno.2013.04.011","title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","year":2013,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Onyx Pharmaceuticals; Bayer HealthCare","keywords":"Medicine; Sorafenib; Front line; Oncology; Ovarian carcinoma; Internal medicine; Randomized controlled trial; Ovarian cancer; Gynecology; Hepatocellular carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007100392,0.0002608952,0.001770517,0.0001715905,0.00005544733,0.000007159058,0.0001268954,0.0002603004,0.00312701],"category_scores_gemma":[0.0003346952,0.0001526128,0.0001988282,0.0001578389,0.000330591,0.00006618576,0.00004544092,0.0002346747,0.0000431488],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004139588,"about_ca_system_score_gemma":0.0006272795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00109553,"about_ca_topic_score_gemma":0.0005298915,"domain_scores_codex":[0.9978492,0.0003833096,0.0007114435,0.0004345778,0.000170807,0.0004507147],"domain_scores_gemma":[0.998019,0.0009197964,0.0003721098,0.0003823767,0.0001680954,0.0001385925],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8917067,0.01637577,0.004319241,0.00002551655,0.0004261415,0.0004798183,0.0007814815,0.00001394784,0.0002833534,0.0007197969,0.0019284,0.0829398],"study_design_scores_gemma":[0.9367949,0.04604767,0.01005868,0.00003445189,0.000173319,0.00003806407,0.0001447302,0.0002334154,0.0004377353,0.0008441895,0.005043533,0.0001492546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736447,0.0005491956,0.0001083436,0.01152899,0.0003977241,0.005732759,0.00001000785,0.00003640513,0.007991865],"genre_scores_gemma":[0.9909604,0.0005442535,0.003245191,0.001343538,0.0001531107,0.002855706,0.00002851377,0.00002087344,0.0008483941],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08279055,"threshold_uncertainty_score":0.9977843,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03282044406175986,"score_gpt":0.3211219546542424,"score_spread":0.2883015105924825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}